

Prime time for Precision Diagnostics driven by unmet Clinical Needs

Program

14 November 2019



08:30 Registration

09.30 Welcome, Host: *Prof. dr. Christa Cobbaert*

Basics and key components of the EFLM Test Evaluation framework

Chair: *Prof. dr. Christa Cobbaert*

09.40 Essentials of the EFLM Test Evaluation framework in the era of IVDR 2017/746

Prof. dr. Patrick Bossuyt, Department of Epidemiology, AMC, Amsterdam, the Netherlands

Applying the basics for test (panel) selection and clinical pathway redesign

Chairs: *Prof. dr. Patrick Bossuyt and Prof dr. Christa Cobbaert*

10.15 The nephrologist viewpoints regarding desirable urine diagnostic support & clinical pathways for reducing kidney injury in secondary and tertiary care hospitals

Prof. dr. Hans de Fijter and dr. Darius Soonawala, Departments of Nephrology, LUMC, Leiden, and Haga Hospital, The Hague, the Netherlands

11.00 The researcher's rationale for selecting a multiplexed biomarker panel for kidney injury based on clinical chemistry needs

Drs. Tirsa van Duijl, Department of Clinical Chemistry and Laboratory Medicine, LUMC, Leiden, the Netherlands

11.25 Predefining clinical performance specifications of potentially useful tests for colorectal cancer screening, as addition to the current iFOBT

Dr. Wilbert van den Hout, Department of Medical Decision Making, LUMC, Leiden, the Netherlands

11.50 Interactive: Questions and answers

12.00 Lunch

Exploring the potential of (glyco-)proteoforms as future medical tests by means of enabling technology

Chairs: Prof. dr. Andy Hoofnagle and dr. Renee Ruhaak

13.00 To be determined

Prof. dr. Andy Hoofnagle, University of Washington, Seattle, Washington, USA

13.30 Understanding the antithrombin measurand using an MS-based antithrombin proteoform method

Dr. Renee Ruhaak, Department of Clinical Chemistry and Laboratory Medicine, LUMC, Leiden, the Netherlands

14.00 An additional layer of clinical information beyond the imperfect total PSA: challenges and opportunities for GLY-PSA?

Dr. Yuri van der Burgt, Centre of Proteomics and Metabolomics and Department of Clinical Chemistry and Laboratory Medicine, LUMC, Leiden, the Netherlands

14.30 Coffee break

Adopting the metrological traceability and commutability concepts into quantitative proteomics applications right from the start: the serum apolipoprotein profile example

Chair: Prof. dr. Andy Hoofnagle and Prof. dr. Christa Cobbaert

14.50 Confounded Lp(a) test results masked clinical utility of Lp(a) test for decades

Prof. dr. Gerhard Kostner, Medical University of Graz, Austria

15.20 The relevance of developing an IFCC MS-based multiplex apoprotein profile method addressing unmet CVD needs

Prof. dr. Uta Ceglarek, University Clinic Leipzig, Germany

15.45 Development of SI-traceable primary reference materials for quantitative proteomics of serum apolipoproteins

Dr. Vincent Delatour, LNE, Paris, France

16.10 Development of SI-traceable and commutable secondary reference materials for quantitative proteomics of serum apolipoproteins

Dr. Liesbet Deprez, JRC, Geel, Belgium

16.30 Interactive: Questions and answers

16.40 Closure

16.45 Reception